Content Type: Article

  • Final SEC Rules Amending Schedule 13G and 13D Beneficial Ownership Reporting

    Final SEC Rules Amending Schedule 13G and 13D Beneficial Ownership Reporting

    ARTICLE / CLIENT ALERT

    Final SEC Rules Amending Schedule 13G and 13D Beneficial Ownership Reporting

    October 13, 2023

    Read time: 9 min

    Key takeaways
    Overview

    On Oct. 10, 2023, the SEC adopted amendments to the rules governing beneficial ownership reporting on Schedule 13G and 13D (“Final Rules”). Since the publication of the proposed rule changes in February 2022[1], market participants have awaited the Final Rules to see how the SEC would balance the competing interests at play.

    As expected, the SEC shortened the filing deadlines applicable to activists filing on Schedule 13D as well as Schedule 13G filers, however, the deadlines adopted are longer than those originally proposed. It determined not to adopt other, more controversial, proposed amendments related to beneficial ownership of shares referenced by certain cash-settled derivatives and group formation (and related proposed exemptions), but instead offered Commission guidance in those areas. Consistent with the proposal, Item 6 of Schedule 13D has been amended to clarify that cash-settled derivatives that reference the applicable issuer’s equity securities are required to be disclosed in Item 6 of Schedule 13D. In addition, as expected, the filing deadline has been pushed to 10 p.m. Eastern Time (instead of 5:30 p.m. Eastern Time on the filing deadline) and Schedules 13D and 13G are now required to be filed using a structured, machine-readable data language.

    Filing Deadlines:

    Initial Filing Deadlines

    • Schedule 13D.
      • As Amended. Five business days following the acquisition of beneficial ownership of more than five percent or losing eligibility to file a Schedule 13G.
      • Prior to Adoption. 10 calendar days following the acquisition of beneficial ownership of more than five percent or losing eligibility to file a Schedule 13G.
    • Institutional and Exempt Schedule 13Gs.
      • As Amended. 45 calendar days after the calendar quarter-end in which beneficial ownership exceeds five percent, computed as of the last day of the calendar quarter.
      • Prior to Adoption. 45 calendar days after the calendar year-end in which beneficial ownership exceeds five percent, computed as of the last day of the calendar year.
    • Accelerated Institutional Schedule 13G.
      • As Amended. Five business days after the end of the month in which beneficial ownership exceeds 10 percent, computed as of the last day of the month.
      • Prior to Adoption. 10 calendar days after the end of the month in which beneficial ownership exceeds 10 percent, computed as of the last day of the month.
    • Passive Schedule 13G.
      • As Amended. Five business days after acquiring beneficial ownership of more than five percent.
      • Prior to Adoption. 10 calendar days after acquiring beneficial ownership of more than five percent.

    Deadlines for Filing Amendments

    • Schedule 13D.
      • As Amended. Two business days following a material change.
      • Prior to Adoption. Promptly following a material change.
    • All Schedule 13Gs.
      • As Amended. 45 calendar days after the end of any calendar quarter if a “material change” has occurred as of the end of the calendar quarter.
        • The “materiality” standard leaves filers with less certainty than they undoubtedly had hoped for. The SEC does not specifically define “material” and instead reiterates that under federal securities laws materiality is an established concept and is deemed to be present under Rule 12b-2 where there is “a substantial likelihood that the disclosure of the omitted fact would have been viewed by the reasonable investor as having significantly altered the ‘total mix’ of information made available.” The SEC states that the fact that the Schedule 13D amendment rule specifies that an increase or decrease in beneficial ownership of one percent or more is deemed to be material for purposes of Schedule 13D amendment obligations is instructive to determine whether a Schedule 13G quarter-end amendment obligation has been triggered, but also notes that acquisitions or dispositions of less than one percent can also be material.
      • Prior to Adoption. 45 calendar days after the end of any calendar year if any change has occurred as of the end of the calendar year.
    • Institutional Schedule 13G.
      • As Amended. Five business days after the end of the month in which beneficial ownership exceeds 10 percent or thereafter increases or decreases by more than five percent, in each case, computed as of the end of the month.
      • Prior to Adoption. 10 calendar after the end of the month in which beneficial ownership exceeds 10 percent or thereafter increases or decreases by more than five percent, in each case, computed as of the end of the month.
    • Passive Schedule 13G.
      • As Amended. Two business days after beneficial ownership exceeds 10 percent or thereafter increases or decreases by more than five percent.
      • Prior to Adoption. Promptly after beneficial ownership exceeds 10 percent or thereafter increases or decreases by more than five percent.

    Filing Day Deadline

    The Final Rules extend the deadline for submitting Schedule 13G and 13D filings from the current 5:30 p.m. Eastern Time to 10 p.m. Eastern Time.

    Reporting of Cash-Settled Derivatives

    The SEC did not adopt a proposed rule which would have made all non-passive holders of cash-settled derivative securities (other than security-based swaps or, SBSs) the beneficial owner of the shares referenced by its cash-settled derivatives, even absent an express right to direct the voting, acquisition or disposition of such shares. Instead, the SEC provided guidance primarily tracking the existing definitions of beneficial ownership under Rule 13d-3(a), (b) and (d) and its 2011 SBS guidance[2] making clear that a holder of a cash-settled derivative security (including SBS) will be considered to be the beneficial owner of the shares referenced by its cash-settled derivative security if such cash-settled derivative security:

    i. Provides its holder, directly or indirectly, with voting or investment power over the underlying shares;

    ii. Is acquired for the purpose or effect of divesting its holder of beneficial ownership of the underlying shares or preventing the vesting of the beneficial ownership as part of a plan or scheme to evade the beneficial ownership reporting requirements; or

    iii. Provides its holder with the right to acquire beneficial ownership over the underlying shares within 60 days if the holder is passive, or, regardless of when the right is exercisable if the holder acquired beneficial ownership of the equity security with the purpose or effect of changing or influencing the control of the issuer, or in connection with or as a participant in any transaction having such purpose or effect – it is noteworthy that the SEC states that this prong would apply to a derivate security that is nominally “cash-settled” or that provides such right based on an “understanding” related to the derivate security.

    Groups

    The proposed rules on group formation and related exemptions were not adopted as part of the Final Rules. Instead, the SEC again opted to provide Commission guidance around group formation.

    The proposed rules included two particularly controversial changes. The first was to remove the requirement that an “agreement” be present among group members and instead include in the definition of group “concerted actions” by two or more persons for the purpose of acquiring, holding or disposing of securities of an issuer. The second was to specify that a group would exist where, in advance of filing a Schedule 13D, a filing person discloses to any other person that such filing will be made if the other person acquires securities subject to the Schedule 13D.

    The Commission guidance will prove comforting to those that feared that the SEC’s group proposal on “concerted actions” could lead to the conclusion that all like-minded investors could be deemed a group. The SEC emphasizes in its guidance that a group requires evidence of an agreement, arrangement, understanding or concerted action and in order for a group to have been formed, at a minimum, indicia, such as an informal arrangement or coordination in furtherance of a common purpose to acquire, hold or dispose of securities or an issuer, must be present.

    The SEC includes specific questions and answers on group formation in the release that are helpful to shareholders looking to understand the risks they run in exchanging views with other shareholders (including activists) and issuers. The guidance is in line with historical SEC guidance, which encourages the exchange of views among shareholders and with issuers without necessarily leading to group formation or the loss of passive status.

    However, the SEC did include guidance stating that a group may exist where, in advance of filing a Schedule 13D, a filer discloses to any other person that such filing will be made if the other person acquires securities as a direct result of the filer’s information. However, more promising than the proposed rules is that the final determination as to whether a group is formed between the filer and the other market participants will ultimately depend upon the facts and circumstances, including (1) whether the purpose of the filer’s communication with the other market participants was to cause them to purchase the securities and (2) whether the market participants’ purchases were made as a direct result of the information shared by the filer. It will remain to be seen whether the SEC’s guidance on this point will have the effect of chilling discussions among activists and other shareholders who do not want to run the risk that the facts will be interpreted in an unfavorable light.

    Disclosure of Derivative Securities

    The SEC did adopt amendments to Item 6 of Schedule 13D to clarify that disclosure of all derivative securities that use the issuer’s equity security as a reference security is required, including disclosure of cash-settled security-based swaps and other cash-settled derivatives. It also adopted amendments to Item 6 to make clear that Item 6 provides an exhaustive list of the types of instruments required to be disclosed.

    Structured Data Requirement

    The Final Rules require Schedules 13D and 13G to be filed using a structured, machine-readable data language.

    Effectiveness and Compliance Dates

    The Final Rules will go into effect 90 days after publication in the federal register. However, compliance with the revised Schedule 13G filing deadlines will not be required before Sept. 30, 2024.

    Authored by Ele Klein, Adriana Schwartz and Clara Zylberg.

    If you have any questions concerning this Alert, please contact your attorney
    at Schulte Roth & Zabel or one of the authors.


    [1]

    [2] Beneficial Ownership Reporting Requirements and Security-Based Swaps, Release No. 34-64628 (June 8, 2011).


    This communication is issued by Schulte Roth & Zabel LLP for informational purposes only and does not constitute legal advice or establish an attorney-client relationship. In some jurisdictions, this publication may be considered attorney advertising. © 2023 Schulte Roth & Zabel LLP. All rights reserved. SCHULTE ROTH & ZABEL is the registered trademark of Schulte Roth & Zabel LLP.

    In depth
    Authors

    Ele Klein

    Partner

    New York – 919 Third Avenue

    More insights

  • California Passes Portions of the Model Money Transmission Modernization Act

    California Passes Portions of the Model Money Transmission Modernization Act

    ARTICLE / CLIENT ALERT

    California Passes Portions of the Model Money Transmission Modernization Act

    October 12, 2023

    Read time: 6 min

    Key takeaways
    Overview

    On Oct. 8, 2023,[1] California Governor Gavin Newsom signed AB-1116[2] into law, which amends certain provisions of California’s Money Transmission Act (Cal. Fin. Code §§ 2000, et seq.) (“MTA”) to align with the Model Money Transmission Modernization Act (“Model Law”).[3] The amended MTA will become effective on Jan. 1, 2024. We note the following changes to the MTA that may be of most relevance to California money transmitter licensees:

    • Repeals Section 2040(e), which will eliminate the limitation that the aggregate value of a licensee’s accounts receivable (excluding money transmission receivables), loans or extensions of credit to any one person (including such person’s affiliates) cannot exceed 50 percent of the licensee’s tangible net worth without the advanced written approval of the California Department of Financial Protection and Innovation (“DFPI”).[4]
    • Adopts the Model Law tangible net worth sliding scale, which will require a licensee to maintain a tangible net worth of “the greater of one hundred thousand dollars ($100,000) or 3 percent of total assets for the first one hundred million dollars ($100,000,000), 2 percent of additional assets for one hundred million dollars ($100,000,000) to one billion dollars ($1,000,000,000), and one-half of 1 percent of additional assets for over one billion dollars ($1,000,000,000).”
    • Adds additional exemptions from the money transmitter licensing requirements for certain entities, including persons that act as an intermediary by processing money transmission transactions for other licensed money transmitters or exempt entities subject to certain conditions, and registered futures commission merchants under the federal commodities laws to the extent of their operation as such merchant. The Amended MTA does not amend or repeal any current exemptions from the money transmitter licensing requirements, including the exemption for payroll processors, even though the Model Law expressly includes payroll processing services in its definition of “money transmission.”
    • Expressly includes as “eligible securities” funds held in an account held for the benefit of a money transmitter licensee’s customers that is titled “(name of licensee) FBO Its (licensee’s customers or specific group of licensee’s customers).” Currently, to count funds held in FBO accounts as eligible securities, licensees must receive express approval from the DFPI.[5] We understand that the amendments will eliminate the need to seek DFPI approval for FBO accounts going forward.
    • Substantially adopts the list of types of permissible investments (known as “eligible securities” in California) contained in the Model Law, including adding an irrevocable letter of credit that meets certain criteria as a type of “eligible security,” in addition to the FBO account described above.
    • Adopts the Model Law definition of “key individual” as a “natural person ultimately responsible for establishing or directing policies and procedures of the licensee, including an executive officer, manager, director, or trustee” and requires a licensee to provide notice to the DFPI within 15 days after the effective date of the key individual’s appointment.
    • Adopts a transitional period, which provides that licensees have until Jan. 1, 2025, to comply with any conflicting or new requirements even though the law becomes effective Jan. 1, 2024. We understand that this provision may apply for example, where a licensee is subject to the current $500,000 statutory tangible net worth requirement. Pursuant to this provision, the licensee would have until Jan. 1, 2025, to increase its tangible net worth requirement to comply with the Model Law’s sliding scale.

    While certain provisions in the amended MTA will likely provide welcome relief to licensed California money transmitters, we note that many California licensees have conditions imposed on them via a “Conditions of Approval” letter issued in connection with the granting of a license, approval of a change of control, or otherwise that may conflict with the amended MTA.[6] It is unclear how the amended MTA will affect these license conditions. The text of the bill, and the accompanying legislative history, do not discuss the interplay between existing license conditions and the amended MTA. We note that the DFPI’s ability to impose conditions on licensees under Section 2036[7] is not affected by the amended MTA. In the absence of guidance from the DFPI, we would recommend that licensees reach out to the DFPI to clarify whether any conditions imposed on them that conflict with the amended MTA are now superseded by such amendments or if the licensee needs to formally seek relief from the DFPI.

    Schulte Roth & Zabel’s lawyers are available to assist you in addressing any questions you may have regarding these developments. Please contact the Schulte Roth & Zabel lawyer with whom you usually work, or any of the following attorneys:

    Donald J. Mosher – New York (+1 212.756.2187)

    Betty Santangelo – New York (+1 212.756.2587)

    Melissa G.R. Goldstein – Washington, DC (+1 202.729.7471)

    Kara A. Kuchar – New York (+1 212.756.2734)

    Adam J. Barazani – New York (+1 212.756.2519)

    Jessica Romano – New York (+1 212.756.2205)

    Jessica Sklute – New York (+1 212.756.2180)

    Noah N. Gillespie – Washington, DC (+1 202.729.7483)

    Jesse Weissman – New York (+1 212.756.2460)


    [1] Office of Governor Newsom, Governor Newsom Issues Legislative Update 10.8.23 (Oct. 8, 2023), available at https://www.gov.ca.gov/2023/10/08/governor-newsom-issues-legislative-update-10-8-23/.

    [2] AB-1116 Money Transmission Act (2023-2024), available at https://leginfo.legislature.ca.gov/faces/billNavClient.xhtml?bill_id=202320240AB1116.

    [3] CSBS Model Money Transmission Modernization Act, available at https://www.csbs.org/sites/default/files/2023-08/CSBS%20Money%20Transmission%20Modernization%20Act.pdf. The following states have also adopted portions or the substantial entirety of the Model Law: Arizona, Arkansas, Connecticut, Georgia, Hawaii, Indiana, Iowa, Minnesota, Nevada, New Hampshire, North Dakota, Rhode Island, South Dakota, Tennessee, Texas, Utah, and West Virginia. CSBS, 2023 Money Transmission Modernization Act Legislation (Aug. 30, 2023), available at https://www.csbs.org/sites/default/files/2023-08/2022%20and%202023%20MTMA%20update%208-30-2023.pdf

    [4] The current language of Section 2040(e) reads as follows: “The aggregate value of a licensee’s accounts receivable, excluding money transmission receivables, loans or extensions of credit to any one person, or that person’s affiliates, cannot exceed 50 percent of the licensee’s tangible shareholders’ equity without the advanced written approval of the commissioner.” Cal. Fin. Code § 2040(e).

    [5] See Cal. Fin. Code § 2084.

    [6] For example, licensees may be subject to a condition to maintain a tangible net worth that is higher than the Model Law sliding scale.

    [7] “The commissioner may impose on any authorization, approval, license, or order issued pursuant to this division any conditions that are necessary for the safety and soundness of the licensee, or reasonable or necessary to maintain or enhance consumer protection.” Cal. Fin. Code § 2036.


    This communication is issued by Schulte Roth & Zabel LLP for informational purposes only and does not constitute legal advice or establish an attorney-client relationship. In some jurisdictions, this publication may be considered attorney advertising. © 2023 Schulte Roth & Zabel LLP. All rights reserved. SCHULTE ROTH & ZABEL is the registered trademark of Schulte Roth & Zabel LLP.

    In depth
    Authors

    Donald J. Mosher

    Partner

    New York – 919 Third Avenue

    Betty Santangelo

    Counsel

    New York – 919 Third Avenue

    Melissa G.R. Goldstein

    Partner

    New York – 919 Third Avenue

    Adam J. Barazani

    Partner

    New York – 919 Third Avenue

    More insights

  • October Forecast: A Busy Month for Climate Change-Related Regulation and Insurers

    October Forecast: A Busy Month for Climate Change-Related Regulation and Insurers

    ARTICLE / CLIENT ALERT

    October Forecast: A Busy Month for Climate Change-Related Regulation and Insurers

    October 11, 2023

    Read time: 6 min

    Key takeaways
    Overview

    SEC CLIMATE FINANCIAL RISK DISCLOSURE: RELEASE OF THE AGENCY’S REVISED REGULATION?

    At some point in October 2023, the US Securities and Exchange Commission (SEC) is expected to release the long-awaited final version of its climate-related financial risk disclosure regulation, first released for public comment in March 2022. Once this regulation is finalized, expect state attorneys general and perhaps private litigants to file lawsuits seeking to invalidate the regulation. These opponents likely will argue that Congress did not explicitly delegate regulatory authority to the SEC related to climate change and climate financial risks, and therefore the SEC’s regulation violates the “major question” doctrine. The Supreme Court of the United States used the major question doctrine last year in West Virginia v. EPA to invalidate an Environmental Protection Agency regulation that would have required power plant operators to go beyond installing scrubbers and change the mix of fuels used to generate electricity in order to reduce air pollution levels.

    Regardless of whether the SEC’s climate risk disclosure requirements are upheld, the SEC enforcement staff is monitoring whether regulated entities—particularly investment advisors—are telling the truth in statements about their consideration of environmental, social and governance (ESG) factors in investment recommendations and decisions. The SEC’s Climate and ESG Task Force, formed in March 2021, coordinates the agency’s ESG enforcement activities, analyzing data from all registrants to “identify potential violations including material gaps or misstatements in issuers’ disclosure of climate risks under existing rules.

    CALIFORNIA: PRO-ESG CLIMATE CHANGE FINANCIAL RISK LEGISLATION SIGNED INTO LAW

    In September 2023, California’s legislature passed landmark climate financial risk disclosure legislation (S.B. 261) and greenhouse gas emission reporting legislation (S.B. 253) that will require many companies “doing business” in the state to prepare and submit climate financial risk disclosures and greenhouse gas emissions reports (audited by outside consultants). On October 7, 2023, California Governor Gavin Newsom signed both bills into law, and they will become effective in 2026 (2027 for reporting of Scope 3 emissions). Insurers (and any entity regulated by the state’s Department of Insurance) are exempt from filing the financial risk disclosure reports, since California-domiciled insurers are already required to file climate risk disclosures using either the National Association of Insurance Commissioners (NAIC) reporting template or by filing Task Force on Climate-Related Financial Disclosures compliant reports.

    Interestingly, on October 8, 2023, Governor Newsom vetoed legislation (A.B. 970) that California Insurance Commissioner Ricardo Lara had championed to create the Climate and Sustainability Insurance and Risk Reduction Program to develop proof of concepts for new insurance options, focusing on communities with uninsured or underinsured climate risks. Had Governor Newsom not vetoed the bill, the state Insurance Department would have funded pilot projects in eight locales around the state to mitigate risks from flooding and extreme heat and to reduce protection gaps in these communities.

    NAIC CLIMATE RISK DISCLOSURE FILINGS

    Colorado will hold a hearing on October 16, 2023, to consider its proposed regulation (#3-1-18) to require all licensed insurers (not just those domiciled in Colorado) to begin filing climate risk financial disclosures in 2024, pursuant to legislation passed earlier this year. Colorado regulators would be well within the bounds of their statutory authority to broaden application of the requirement. If they do promulgate a final regulation along these lines, Colorado will be the first state to require reporting by all licensed insurers. Not even California, New York or Washington State went that far.

    Comments on the proposed regulation can be submitted up to the close of business on October 19, 2023. It will be interesting to see if any regulators from the more than 20 anti-ESG states submit comments to their fellow regulators.

    FINANCIAL ANALYSIS SOLVENCY TOOLS (E) WORKING GROUP AND FINANCIAL EXAMINERS HANDBOOK (E) TECHNICAL GROUP

    Responding to the NAIC’s Climate and Resiliency Task Force referral from May 2022, two technical/working groups have been drafting and considering climate-related financial risk “enhancements” to the Financial Analysis Handbook 2023/2024, the guide for financial examiners when planning and executing periodic financial examinations of admitted insurers. During the working group’s meeting on October 2, 2023, regulators voted to include climate-related “material” financial risk categories in the handbook for both investment and underwriting risk.

    With respect to investment risk, the handbook encourages examiners to review insurer climate financial risk disclosures in the NAIC’s climate financial risk filings, insurer disclosures in ORSA filings, SEC filings (when, and if, SEC finalizes climate financial risk disclosures) and the NAIC’s Industry Climate Affected Investment Analysis.

    On the underwriting risk side, the handbook encourages analysts “to review insurer Schedule Ts to spot material concentrations of premium in cat-exposed jurisdictions and to review property and casualty insurers’ cat risk charge filings, including reviewing modeled loss outputs from an approved cat risk model (compare to California’s current regulatory prohibition on the use of cat models in rate-making).

    The handbook will also encourage analysts to review insurers’ current reinsurance arrangements and future costs/availability in light of climate financial risk considerations, per this new wording: “The insurer’s reinsurance strategy may not be sustainable due to increasing cost and availability concerns on a prospective basis.”

    US DEPARTMENT OF THE TREASURY REPORT: “THE IMPACT OF CLIMATE CHANGE ON AMERICAN HOUSEHOLD FINANCES”

    In a report published at the end of September 2023, Treasury and other agencies studied the negative impact of climate hazards and conditions on US households. The report analyzed elements beyond the narrow (although obviously important) impact of property damage from climate/weather events. Key factors prompting preparation of the report included the following:

    • From 2018 to 2022, the total cost of “major” weather and climate disasters was more than $617 billion.
    • In 2022 alone, the cost was more than $176 billion.
    • Of all US residents, 13% reported “economic hardship” related to climate/weather disasters.
    • One-third of US counties reported “heightened” exposure to flooding, wildfire and/or extreme heat risks.
    • In 2021, climate and weather hazards impacted one in 10 homes.

    The key findings in this report had to do with the non-property damage impacts on households struggling to keep up, living in a “paycheck-to-paycheck” world. The report cites a 2022 Federal Reserve Board study finding that 63% of households could not cover a $400 emergency expense with cash on hand. The non-property damage impacts from cat events and climate change conditions identified in the Treasury report ranged from lost wages, delays in receiving benefit program payments, supply chain disruptions leading to higher prices and increased energy costs for cooling due to rising temperatures.

    We will be monitoring climate change developments around the states, at the NAIC and in Washington, DC, in the run-up to both the NAIC’s next national meeting in Orlando and the next UN Conference of the Parties (#28) in Dubai. Both events are scheduled to begin on November 30, 2023.

    In depth

    xxx

    Authors

    Thomas M. Dawson

    Partner

    New York – One Vanderbilt Avenue

    More insights

  • UK-US Data Bridge: An Extension to EU-US Data Privacy Framework

    UK-US Data Bridge: An Extension to EU-US Data Privacy Framework

    ARTICLE / CLIENT ALERT

    UK-US Data Bridge: An Extension to EU-US Data Privacy Framework

    October 10, 2023

    Read time: 4 min

    Key takeaways
    Overview

    The UK government has published the Data Protection (Adequacy) (United States of America) Regulations 2023 (SI 2023/1028) (the UK-US Data Bridge Regulations) which adopted an adequacy decision for the US (the UK-US Data Bridge) and will come into force on 12 October 2023.

    The UK-US Data Bridge recognizes the US as offering an adequate level of data protection where the transfer is to a US organization that (i) is listed on the EU-US Data Privacy Framework (DPF), and (ii) participates in the UK Extension to the DPF.

    On July 10, 2023, the European Commission adopted its adequacy decision for the DPF. The decision concluded that the DPF ensures an adequate level of protection for transferring personal data from the European Union to the United States. The UK-US Data Bridge is an extension of the DPF which was discussed in our prior updates.

    In depth

    What are therefore the advantages of using the DPF and the UK-US Data Bridge?

    Leveraging the DPF, recognized as an adequacy decision, provides organizations with a streamlined approach to data transfers. Within this context, companies that participate in the DPF are automatically deemed safe for data reception from the UK.

    One of the prime benefits of the UK-US Data Bridge, built upon the DPF framework, is that participating organizations are exempted from the need to conduct transfer impact assessments (TIAs) or institute supplementary measures. In contrast, if companies rely on Standard Contractual Clauses (SCCs) or Binding Corporate Rules (BCRs), they are still mandated to implement supplementary measures. The UK-US Data Bridge facilitates a seamless transfer of data back and forth between the two territories. Furthermore, as the data protection landscape evolves, customers increasingly expect companies to actively participate in such data transfer framework, enhancing trust and compliance.

    Are there any challenges?

    However, not all is without complications. Both the Information Commissioner’s Office (ICO) and EU privacy activists have commented on the UK-US Data Bridge and the DPF. The ICO noted in its opinion on the UK-US Data Bridge Regulations that there are areas that could pose risks to UK data subjects if the protections identified are not properly applied. The opinion identifies several potential issues with the UK-US Data Bridge, including the following, serve as a basis to question the UK-US Data Bridge:

    • The UK-US Data Bridge does not contain substantially similar rights to the UK GDPR’s (i) right to be forgotten, (ii) right to withdraw consent, and (iii) right to obtain a review of an automated decision by a human. As a result, UK data subjects might not have the same level of control over their data as they do under UK GDPR.
    • The definition of ‘sensitive information’ under the UK-US Data Bridge does not specify all the ‘special categories of personal data’ of the UK GDPR. Instead, the framework has a broad ‘umbrella’ concept providing that sensitive information can be any data regarded as sensitive by the transferring entity. UK businesses will have to clearly label certain types of data as ‘sensitive’ when transferring to a US organisation certified under the UK Extension to ensure adequate protection.
    • For data on criminal offenses, the ICO highlights potential vulnerabilities, even when tagged as sensitive. Since the UK places restrictions on the use of ‘spent’ convictions, there are concerns about a lack of comparable protections in the US for transferred data.

    Conclusion

    While the DPF and UK Data Bridge present advantages for companies aiming for seamless data transfers from the EU or the UK to the US, they are not without challenges.

    The DPF and the UK-US Data Bridge extension are not the only option organisations transferring and processing personal data outside of the UK have. Controllers or processors may still choose to rely on other appropriate safeguards such as standard contractual clauses or binding corporate rules.

    We are witnessing a growing trend among organisations to put in place diverse safeguard measures, preparing for the eventuality that one of these transfer mechanisms might be invalidated. Companies interested in discussing the individual needs of their organisation should contact the authors or their regular McDermott lawyer.

     

    Authors

    Sharon Lamb

    Partner

    London – 22 Bishopsgate

    Pilar Arzuaga

    Partner

    London – 22 Bishopsgate

    More insights

  • DEA Further Extends Flexibilities for Controlled-Substance Prescribing via Telemedicine

    DEA Further Extends Flexibilities for Controlled-Substance Prescribing via Telemedicine

    ARTICLE / CLIENT ALERT

    DEA Further Extends Flexibilities for Controlled-Substance Prescribing via Telemedicine

    October 6, 2023

    Read time: 6 min

    Key takeaways
    Overview

    The United States Drug Enforcement Administration (DEA) and the Substance Abuse and Mental Health Services Administration (SAMHSA) have further extended flexibilities that allow providers to prescribe controlled substances via telemedicine without first performing an in-person visit. The flexibilities were initially provided during the COVID-19 public health emergency (PHE). The extension runs through December 31, 2024.

    The DEA anticipates releasing a final rule addressing telemedicine prescription of controlled substances in fall 2024.

    In depth

    On October 6, 2023, the DEA and SAMHSA issued a temporary rule that will extend the full set of telemedicine flexibilities adopted during the PHE through December 31, 2024. This extension, which follows an earlier temporary rule issued in May 2023, authorizes all DEA-registered practitioners to prescribe schedule II-V controlled medications via telemedicine through December 31, 2024, regardless of when the practitioner-patient relationship was established. (Under the May 2023 temporary rule, the extension allowed the prescription of a controlled substance without a previous in-person examination only for relationships established on or before November 11, 2023, and only until November 11, 2024.)

    BACKGROUND

    Under the Ryan Haight Act of 2008, a telemedicine provider was first required to perform an in-person medical evaluation of a patient prior to prescribing a controlled substance (with certain limited exceptions). The controlled substance-prescribing flexibilities invoked in March 2020 in response to the PHE, which allowed for prescribing controlled substances via telemedicine without an initial in-person visit, were set to end with the termination of the PHE on May 11, 2023.

    In February 2023, the DEA and SAMHSA proposed two rules (the General Telemedicine Rule and the Buprenorphine Rule), which would have established additional potential pathways for prescribing certain controlled substances in limited quantities via telemedicine without an initial in-person medical examination, while also imposing detailed recordkeeping requirements.

    Notably absent from the proposed rules was a “special registration” process. Under the Ryan Haight Act, a prior in-person medical evaluation is not required if the practitioner holds a special registration. However, in the 14 years since the act’s passage, the DEA has failed to establish the special registration process for qualified providers (even though Congress imposed a deadline of October 2019 in the 2018 SUPPORT for Patients and Communities Act (SUPPORT Act) for the promulgation of final regulations for the special registration process). In the proposed rules, the DEA opted not to implement the special registration process and instead invoked its authority under a different provision of the Ryan Haight Act. (See our Special Report: DEA Proposes Limited Post-PHE Telemedicine Prescription of Controlled Substances for more details on the proposed rules.)

    The DEA received a record 38,000 comments in response to the proposed telemedicine rules, including comments from federal lawmakers. Many stakeholders pointed out that the requirement for an in-person evaluation would make it more challenging for certain patients facing significant barriers to accessing care without telemedicine to continue receiving the controlled medications they need. Subsequently, the DEA issued the May 2023 temporary rule, extending telemedicine flexibilities adopted during the PHE through November 11, 2023, for new patients, and November 11, 2024, for patients established on or before November 11, 2023. It also indicated that it would be further evaluating its proposed telemedicine rules in light of the comments.

    DEA LISTENING SESSIONS

    The October 2023 temporary rule comes on the heels of a two-day listening session in which the DEA heard from healthcare practitioners, experts, advocates, patients and other members of the public regarding the prescription of controlled substances via telemedicine, along with potential safeguards to prevent and detect the diversion of controlled substances prescribed via telemedicine.

    Sixty-one commenters spoke during the session. Key themes:

    • Commenters were largely supportive of a special registration for telemedicine prescription of schedule II-V controlled substances, although no best practice emerged.
    • Pharmacists were concerned they would bear the brunt of burdensome checks and data collection for the new regulations.
    • Palliative-care and end-of-life advocates requested an exemption to the in-person requirement for those in hospice or similar end-of-life care.
    • There was no consensus among the commenters on the in-person prescription requirement. Several of them emphasized that the prescribing of controlled substances via telemedicine during the PHE increased access to care and decreased relapse rates, particularly for patients seeking treatment for substance-use disorders. These commenters generally stated that in-person visits are not necessary and that providers should use their medical judgment in determining when an in-person visit would be indicated. Other commenters argued that an initial in-person visit should be required and expressed concerns about the diversion of controlled substances.
    • Overall, the commenters agreed that regulations should not increase practitioner burden and that the DEA should leverage data from existing sources to monitor telemedicine prescribing practices. Some commenters suggested that the DEA consider establishing a national prescription drug monitoring program.

    Lawmakers have also been following this issue closely. After the listening session, a bipartisan group of senators wrote to the DEA, expressing concerns with the current proposed rule and imploring the DEA to create a special registration process. They cited the SUPPORT Act’s requirement and noted that the goal of the special registration is to allow medical evaluations over telehealth more broadly, which the senators stated the proposed rule does not accomplish. The DEA’s actions will continue to be closely scrutinized by policymakers.

    WHAT’S NEXT?

    The DEA has extended the telemedicine flexibilities adopted during the PHE through December 31, 2024, and will continue to evaluate the information it received during the listening session, as well as the 38,000 comments on the proposed rules. The DEA anticipates releasing a final rule in fall 2024. During the listening session, the DEA indicated there may also be another written comment period this fall.

    Authors

    Amanda Enyeart

    Partner

    Chicago

    Marshall E. Jackson , Jr.

    Partner

    Washington, DC

    Lisa Mazur

    Partner

    Chicago

    Patrick Zanayed

    Partner

    Chicago

    Grayson I. Dimick

    Associate

    Washington, DC

    Jayda Greco

    Partner

    Chicago

    More insights

  • Employer Student Loan Debt Benefits Following SECURE 2.0

    Employer Student Loan Debt Benefits Following SECURE 2.0

    ARTICLE / CLIENT ALERT

    Employer Student Loan Debt Benefits Following SECURE 2.0

    October 4, 2023

    Read time: 11 min

    Key takeaways
    Overview

    Our September 12, 2023, webinar explored how organizations can provide student loan repayment benefits to their workforces and leverage them to increase employee satisfaction and retention. Watch the recording “SECURE 2.0: The impacts of employer matching for student loan payments” to learn more.


    In December 2022, Congress enacted groundbreaking legislation as part of the SECURE 2.0 Act (SECURE 2.0) codifying an opportunity for employers to provide matching contributions within a tax-qualified retirement plan based on their employees’ qualified student loan payments outside the plan. The SECURE 2.0 student loan payment match is the latest vehicle for employers to aid employees to help relieve the financial burden of student loan debt.

    This On the Subject discusses the SECURE 2.0 student loan benefit and other employer options for providing tax-advantaged benefits to employees based on student loan payments. It also examines the open questions and current implementation challenges for sponsors of 401(k) and 403(b) plans hoping to implement the student loan benefit.

    In depth

    THE STUDENT LOAN DEBT PROBLEM AND EMPLOYER RESPONSE

    Over the last two decades, the amount of outstanding student loan debt in the United States has grown exponentially. Studies suggest there are currently around 43 million Americans with student loan debt of more than $1.6 trillion. Paying off student loan debt has become a hot-button political issue, including with presidential candidates and members of Congress. Earlier this summer, the US Supreme Court’s decision in Biden v. Nebraska rejected the Biden administration’s plans for student loan debt relief. The Supreme Court held that the Higher Education Relief Opportunities for Students Act of 2003 did not authorize the secretary of education to cancel approximately $430 billion in federal student loan principal. This decision comes as the statutory pause on student loan repayments ended on September 1, 2023, a moratorium enacted in response to the COVID-19 pandemic and lasting over three years.

    Managing student loan debt has become an increasingly significant issue for many workers. As a result, student loan debt presents a significant opportunity for employers. Student loan repayment programs can be a key factor in attracting and retaining talent. In a 2019 survey conducted by Gradifi, a student loan benefits provider, 70% of employees said they were likely to stay at their current jobs because a student loan paydown plan was available. Ninety-seven percent of employees reported being happier in their place of employment because of a student loan repayment program. Ninety-two percent of employees reported feeling an improvement in their stress because of their employer’s student loan repayment program. As a result, many employers are investigating new options to stay competitive and help their employees tackle student loan debt.

    OPTIONS FOR EMPLOYERS TO PROVIDE TAX-ADVANTAGED STUDENT LOAN DEBT BENEFITS

    Unfortunately, there are limited ways for employers to structure a program to provide student loan debt assistance that is not subject to immediate income tax. The current vehicles for providing student loan debt benefits on a tax-advantaged basis are:

    Educational Assistance Programs

    As part of the Coronavirus Aid, Relief, and Economic Security Act of 2020 (CARES Act), Congress amended Section 127 of the Internal Revenue Code (Code) to permit employers to pay up to $5,250 per year to employees for student loan repayments as part of an educational assistance program. Many employers utilize such plans to provide tuition reimbursement for college or advanced degrees. Under the CARES Act, employers may also utilize these plans to provide student loan debt assistance.

    To do so, employers must comply with the requirements of Section 127 of the Code, including:

    • The employer must have a written plan document that lays out the terms of the program;
    • The program must benefit employees or certain former employees who qualify under rules set up so that the program does not favor highly compensated employees;
    • The program must not provide more than 5% of its benefits during any year for shareholders or owners (or their spouses or dependents) who own more than 5% of the stock or of the capital or profits interest of the business;
    • The program must not allow employees to choose to receive cash or other benefits that would be included in gross income instead of educational assistance; and
    • Eligible employees must be given reasonable notice of the program.

    An educational assistance program provides a direct ability to pay off student loan debt through a basic but effective tax structure. Employers can make payments either to employees or directly to lenders. Many employers who offer student loan repayment benefits work with a third-party vendor because the employer does not want to be in the position of asking employees for sensitive financial information regarding student loan debt. Vendors often work with lenders either to pay off student loan debt directly or, if the employer provides direct payment to employees, to track or verify student loan debt payments so that the employer can be certain the payments are being used to pay off student loan debt.

    The $5,250 limit is the combined limit for all educational assistance, including both expenses related to tuition reimbursement and student loan debt payments. Under current law, the ability for employers to pay up to $5,250 per year to employees for student loan debt payments as part of an educational assistance program expires on December 31, 2025. However, it is often the case that employee benefit options enacted through the Code which are originally scheduled to sunset are extended indefinitely or made permanent. There is no guarantee, but it would not be surprising if the student loan debt payment benefit is extended or made permanent, particularly in the current environment where student loan debt receives significant media attention.

    Contributions to Tax-Qualified Retirement Plans

    In 2018, the Internal Revenue Service (IRS) released a groundbreaking private letter ruling (PLR) that helped to clear the way for employers to begin providing student loan repayment benefits as part of their 401(k) plans. The PLR confirmed that, under certain circumstances, 401(k) plan sponsors may link the amount of employer contributions made on an employee’s behalf to the amount of student loan debt payments made by the employee outside the plan. However, the PLR only applied to the specific plan sponsor requesting the ruling and did not address the effect on many other plan qualification requirements, such as the Code Section 401(a)(4) nondiscrimination requirement.

    SECURE 2.0 codified the ability for certain defined contribution plan sponsors to provide employer-matching contributions based on employee payment of student loan debt. Effective for plan years after December 31, 2023, 401(k) and 403(b) plan sponsors can provide employer-matching contributions based on an employee’s “qualified student loan payments” made outside of the plan. A qualified student loan payment includes any payment made by an employee in repayment of a qualified higher education loan. The loan must be for the cost of attendance at an eligible educational institution.

    SECURE 2.0 provided a helpful statutory framework for plan sponsors to provide matching contributions on student loan payments. Some of the most significant features are:

    • “Qualified student loan payments” can include payments made by an employee for student loans made on behalf of the employee, the employee’s spouse or dependent;
    • Plan sponsors are permitted to rely on an employee’s self-certification of qualified student loan payments, which certification must be made on an annual basis;
    • Matching contributions on student loan payments must be treated the same as matching contributions made on elective deferrals concerning the match percentage, eligibility and the same vesting rules (though match frequency can differ);
    • Plan sponsors may make the student loan match more frequently than annually (e.g., on a payroll period basis), but employees must have at least three months after the close of the plan year to claim the match;
    • Qualified student loan payments are treated as available to all participants for purposes of the Code Section 401(a)(4) nondiscrimination testing requirements;
    • Student loan payments can be treated as elective deferrals for safe harbor plan rules; and
    • For purposes of the Actual Deferral Percentage (ADP) test, plan sponsors may separately test participants who receive matching contributions on account of qualified student loan payments.

    OUTSTANDING QUESTIONS REGARDING SECURE 2.0 STUDENT LOAN EMPLOYER MATCHING CONTRIBUTIONS

    While SECURE 2.0 provided the framework for the implementation of the student loan match, many open questions remain, and the US Department of the Treasury (Treasury) and IRS need to provide more guidance to fully implement this feature. Some specific areas where guidance would be helpful include:

    • More guidance on what constitutes a qualified student loan payment. It seems clear that payment made by an employee toward a loan taken by an employee, employee’s spouse or dependent qualifies, but when is this determined? What if the employee’s spouse or dependent was a spouse or dependent when the loan was taken, but not when the loan payments are made (or vice versa)?
    • What is required for a plan sponsor to establish reasonable procedures regarding annual self-certification? Separately, are there any limits on how much substantiation a plan sponsor can require if it wants to?
    • If the match is allocated after the end of the year, can it be limited to active employees? Would this apply to safe harbor plans (which generally are not permitted to require service as of the last day of the plan year for employees to receive contributions) as well?
    • How does the ability of employees to claim the match within three months after the end of the plan year affect the general requirement for non-safe harbor plans to correct ADP and Actual Contribution Percentage testing failures within two-and-a-half months after the end of a plan year to avoid an excise tax?
    • How do the vesting requirements work? The student loan match must vest “in the same manner” as a regular match. How does this work if the plan has a fully vested safe harbor match plus a discretionary match subject to a vesting schedule?

    SECURE 2.0 directs the Treasury to issue regulations to address these and other questions and establish reasonable procedures and deadlines for employees to take advantage of the student loan match benefit.

    PLAN SPONSOR CHALLENGES IMPLEMENTING SECURE 2.0 STUDENT LOAN DEBT BENEFITS

    In addition to the open legal questions, numerous other challenges exist for plan sponsors seeking to implement the SECURE 2.0 student loan matching contribution. Most significantly, plan sponsors need to assess their ability to implement a student loan benefit within the context of their existing 401(k) or 403(b) plan platform. The plan’s recordkeeper and third-party administrator must have systems set up to administer the student loan debt benefit. Due in part to the ongoing questions and lack of guidance, many recordkeepers have delayed the development of the systems set up to administer student loan debt benefits on a large scale beginning in 2024. Some have set up pilot programs to test the option for a handful of plans. Many recordkeepers and administrators are just starting to “pilot” their process and systems for 2024 before making the offering available more widely, which may be in 2025 or 2026.

    Employers pondering a SECURE 2.0 student loan benefit should consider the following:

    • Is the benefit right for your employee population? For some employers the answer is obvious: They either have a significant number of employees with college or advanced degrees for whom this issue is a high priority, or they do not. For others, it can be useful to assess the employee demographics to estimate the proportion of employees who may be interested in a student loan match. Some 401(k) recordkeepers are developing data and programs to help their clients make this determination. Some employers have utilized polls or surveys to try to determine employee interest.
    • What is the potential cost? Employers can model cost projections based on expected participation rates. Some recordkeepers are developing data and programs to help their clients make this determination.
    • Are there other, more effective ways to provide student loan debt benefits? For example, the CARES Act educational assistance program benefit discussed above is a relatively straightforward way to provide direct student loan debt benefits.

    Although challenges remain, plan sponsors should keep in mind that plan design features are constantly evolving, and implementation issues always take time. Many retirement plan practitioners believe that it is only a matter of time before the student loan employer matching contribution becomes a commonplace feature within most employers’ 401(k) or 403(b) retirement plans.

    Authors

    Jeffrey M. Holdvogt

    Partner

    Chicago

    Brian J. Tiemann

    Partner

    Chicago

    More insights

  • Laboratory-Developed Tests: FDA Publishes Highly Anticipated Proposed Rule

    Laboratory-Developed Tests: FDA Publishes Highly Anticipated Proposed Rule

    ARTICLE / CLIENT ALERT

    Laboratory-Developed Tests: FDA Publishes Highly Anticipated Proposed Rule

    October 4, 2023

    Read time: 7 min

    Key takeaways
    Overview

    On September 29, 2023, the US Food and Drug Administration (FDA) published a long-awaited proposed rule on laboratory-developed tests (LDTs). If FDA finalizes this rule as proposed, FDA will regulate virtually all LDTs as medical devices.

    It has long been FDA’s position that the Food, Drug, and Cosmetic Act gives it authority to regulate LDTs as medical devices. Historically, FDA has exercised enforcement discretion with respect to most LDTs and has not required the laboratories offering such tests to comply with FDA regulatory requirements for medical devices. In the proposed rule, FDA proposes to modify its regulations to explicitly state that in vitro diagnostics (IVDs) are devices, including when the manufacturer of the IVD is a clinical laboratory.

    In depth

    If finalized as proposed, this change will impose significant new regulatory requirements on nearly all clinical laboratories currently offering tests as LDTs. Key aspects of the agency’s proposal include the following:

    • Enforcement discretion would end in five stages over a four-year period from the date FDA publishes a final rule:
      • Phase 1 (effective one year post-finalization): Labs must comply with medical device (adverse event) reporting and correction/removal reporting requirements.
      • Phase 2 (effective two years post-finalization): Labs must comply with all other device requirements (e.g., registration/listing, labeling, investigational use), except for quality systems and premarket review.
      • Phase 3 (effective three years post-finalization): Labs must comply with quality systems requirements.
      • Phase 4 (effective three and a half years post-finalization, but not before October 1, 2027): Labs must comply with premarket review requirements for high-risk tests (i.e., tests subject to premarket approval (PMA) requirement).
      • Phase 5 (effective four years post-finalization, but not before April 1, 2028): Labs must comply with premarket review requirements for moderate- and low-risk tests (i.e., tests subject to de novo or 510(k) requirement).

    Tests offered as LDTs—including those that fall outside of FDA’s historically narrow definition of what constitutes an LDT (i.e., a test intended for clinical use that is designed, manufactured and used within a single high-complexity Clinical Laboratory Improvement Amendments (CLIA) laboratory)—may remain on the market until FDA completes its review of the lab’s application.

    In the interim, FDA notes that it “retains discretion to pursue enforcement action at any time against violative IVDs when appropriate.”

    • There would be no grandfathering for existing tests, including tests performed at academic medical centers (AMCs), but the agency requests comments on this approach. In previous agency statements (e.g., its 2017 discussion paper), FDA expressed its willingness to grandfather many existing tests from most or all FDA regulatory requirements. The proposed rule, however, does not include any express grandfathering provision. Anticipating that it will receive comments on this point, the agency requests that any comments supporting grandfathering include both an explanation of the public health rationale for grandfathering (including supporting data) and an outline of steps to help support a grandfathering approach, including ideas to help address FDA’s concerns about grandfathered test performance.

    FDA also requests information on how it might leverage the New York State CLEP and Veterans Administration programs, respectively. In particular, FDA requests comments on whether it should continue to exercise enforcement discretion with respect to tests that successfully participate in those programs.

    FDA also requests comments on whether it should continue enforcement discretion for tests offered at AMCs.

    • Tests offered in a single CLIA-certified laboratory would be subject to a subset of the usual “device” quality systems requirements. For tests where all manufacturing activities occur within a single CLIA-certified clinical laboratory and for which distribution does not occur outside that single laboratory, FDA expects compliance with some, but not all, quality systems requirements. Specifically, labs must comply with the following:
      • Design controls (21 CFR 820.30)
      • Purchasing controls (21 CFR 820.50)
      • Acceptance activities (21 CFR 820.80 and 820.86)
      • Corrective and preventive actions (820.100)
      • Records requirements (21 CFR 820, Subpart M).

    For all other IVDs offered as LDTs, FDA proposes to end enforcement discretion for all quality systems requirements three years after finalization.

    The proposed rule is open for comment until December 2, 2023.

    Analysis

    If finalized as proposed, the rule would impose significant new regulatory requirements on clinical laboratories offering LDTs.

    The agency’s proposal also raises several critical (and unanswered) questions:

    • Does the agency have legal authority to regulate LDTs? Notwithstanding the agency’s contention, this issue has not been conclusively addressed by the courts. Any final rule will almost certainly be subject to legal challenge(s) by interested laboratory stakeholders.
    • How will FDA address the practical issues associated with regulating LDTs as medical devices? Unlike an IVD test kit, an LDT is not a physical item that is transferred in interstate commerce. Therefore, what is the regulated “device” within the laboratory test operation? To whom would LDT labeling be addressed—the performing laboratory or the ordering physician? And perhaps most importantly, how will FDA find the resources necessary to timely review the additional submissions that would come in under the framework?
    • Will the proposed rule change the industry’s (or Congress’s) position on the Verifying Accurate, Leading-edge IVCT Development (VALID) Act)? FDA and other interested stakeholders have been working on a legislative approach specific to diagnostics that would clarify FDA’s authority over LDTs. Compared to FDA’s proposal, VALID includes several provisions that are more favorable to clinical laboratories, including explicit grandfathering and an extended timeline for compliance. For a high-level comparison between the proposed rule and VALID, please see this chart. While Congress was close to a compromise on VALID at the end of 2022, no final agreement was reached. The leaders of VALID are reviewing this proposed rule and possibly renewing their efforts to pass the legislation. While some lawmakers, including lead Republicans on the US House of Representatives and US Senate committees of jurisdiction, have already released statements raising questions and concerns on the proposed rule, it is unclear if they would support a legislative effort.
    • Will FDA maintain the proposed phase-in timeline in a final rule? The timeline in the proposed rule is substantially more aggressive than the timeline in the FDA’s 2014 draft guidance (up to nine years, for certain tests). The volume of tests has increased substantially since 2014, making it questionable whether FDA has the resources to review a large volume of premarket review submissions within the timeframe indicated. Stakeholders likely will seek a longer timeframe for compliance or congressional direction to delay implementation.
    • Will the agency reverse course and allow some type of grandfathering for existing tests? And if so, to what extent?
    • What guidance will FDA make available to clinical laboratories? How will laboratories know whether their tests are high risk (and subject to the PMA requirement within three and a half years) or moderate/low risk (and subject to the 510(k) or de novo requirement within four years)? Clinical laboratories have not historically been subject to FDA quality systems requirements and therefore may find it difficult to come into compliance with such requirements (particularly design controls). The extent to which the agency will provide laboratories with additional guidance to facilitate their compliance with such requirements is unclear.
    Authors

    Michael W. Ryan

    Partner

    Washington, DC

    Paul W. Radensky , MD

    Counsel

    Washington, DC, Miami

    More insights

  • Texas Taxing 130% of Marketplace Sales

    Texas Taxing 130% of Marketplace Sales

    ARTICLE

    Texas Taxing 130% of Marketplace Sales

    Oct 3, 2023

    Read time: 5 min

    Key takeaways
    Overview

    Proving that everything is bigger in Texas, the state’s Comptroller is now assessing marketplace providers on 130% of their sales. It seems a sales tax on 100% was not big enough for tax officials in the Lone Star State. The additional 30% is a tax on the portion of the product sales price kept by marketplace providers. Talk about double dipping…

    Like all states following the Wayfair decision, Texas adopted a marketplace law in 2019 that required marketplace providers to charge tax on 100% of the sales price for products sold over the platform by third-party sellers. Apparently unsatisfied, the Texas Comptroller has decided to assess tax on 130% of marketplace sales, with the additional 30% a double tax on the portion of the sales proceeds paid to the marketplace provider as a commission.

    In most marketplaces, the provider charges a commission for allowing a third-party seller to use the platform and its services, like advertising and access to the platform’s user base. As most commissions are typically in the 30% range, Texas is demanding that marketplace providers pay tax on 130% of the sales price and charge the consumer for tax on the 100% and the seller for the 30%.

    Without notifying the public, Texas is asserting, on audit, that these commissions are taxable. This position is contrary to a long-standing administrative ruling that was issued in 2012 and quietly revoked by the Texas Comptroller in 2020.

    A quick example illustrates how aggressive this position is and the negative impact it will have on marketplace sellers in Texas: Take a book collector in Austin who is selling used books through a marketplace provider and sells a $100 rare Bible to a customer in Dallas. Historically, the marketplace provider would charge an 8% sales tax on the $100 Bible and send that $8 to the Texas Comptroller.[1] The marketplace provider would then take its $30 commission and send the balance of $70 to the local bookseller.

    Now, the Texas Comptroller is telling the marketplace provider, on audit, that the $30 commission it received is separately subject to the sales tax. The marketplace provider in the example should have collected an additional $2.40 in sales tax on its receipt of the commission, resulting in an effective sales tax rate on the transaction of 10.4% (again, with no legislative authority or change behind this view). Instead of getting $70 in revenue, the bookseller will only receive the net after sales tax, or $67.60.[2] While this reduction may not seem like much, it will be the difference between being profitable and losing money for some Texas-based sellers. For the Texas Comptroller to make this policy change without legislative blessing—and while the state is enjoying a record budget surplus—should raise alarm bells.

    How does the Texas Comptroller get there? First, it deems the commission payment a transaction separate and distinct from the underlying sale of the Bible in the above example. Second, it looks at the services the marketplace provider offered the bookseller and concludes that those services are the provision of taxable data processing representing more than 5% of the total charge.[3] With this change, the Texas Comptroller is limiting the sourcing determination to commissions paid by sellers located in Texas, though it wants to tax all transactions regardless of where the product is shipped.

    How is the Texas Comptroller enforcing its position? By auditing marketplace providers and asserting deficiencies for failing to collect and remit the sales tax on the commission payments by sellers in Texas. The problem for many marketplaces is that there’s no second “transaction” in their business model and the tax calculation software won’t function if there’s no transaction to run through the system. Even if there are two entries as part of the transaction, Texas wants to source them differently; the good to where it is shipped and the commission to where the seller is located. These problems make it impossible for many to comply with these new demands of the state.

    Are there defenses to the Texas Comptroller’s audit position? You bet. The state’s view is premised on a belief that everything that touches a computer is data processing. However, that is just not the case. Individual company facts will be important in determining whether you’re selling data processing. However, in the cases we’ve seen, providers are charging a commission for access to the platform and its customer base.

    While we expect this issue to make its way to the courts, we are at the beginning of a battle at the Alamo that likely will last the next five years.

    The good news for some is that Texas is making marketplace providers a go-forward offer they can’t refuse. If you are in this situation and need advice on navigating this new and complex Texas discussion, please reach out to the authors of this article.

    Authors

    Stephen P. Kranz

    Partner

    Washington, DC

    Mark Nebergall

    Counsel

    Washington, DC

    Eric D. Carstens

    Partner

    Washington, DC

    More insights
    Endnotes

    [1] Texas has a variety of local rates, and the average is about 8%. This example assumes the purchaser is in a locality with an 8% total sales tax rate and the bookseller is in Texas.

    [2] To keep the example simple, we ignored the 20% exemption for data processing services.

    [3] Tex. Tax Code §§ 151.0101(12), 151.0035., 34 Tex. Admin. Code § 3.330(d)(2).


  • Walking the Walk: FTC Lawsuit Targets Private Equity Roll-Up Strategy

    Walking the Walk: FTC Lawsuit Targets Private Equity Roll-Up Strategy

    ARTICLE / CLIENT ALERT

    Walking the Walk: FTC Lawsuit Targets Private Equity Roll-Up Strategy

    October 2, 2023

    Read time: 10 min

    Key takeaways
    Overview

    What happened?

    On Sept. 21, 2023, the Federal Trade Commission (“FTC”) sued US Anesthesia Partners (“USAP”) and its private equity backer, Welsh, Carson, Anderson & Stowe LP (“Welsh Carson”), alleging that USAP and Welsh Carson violated antitrust law through a three-pronged scheme to monopolize the anesthesiology market in Texas to drive up prices and increase profits. In its complaint, filed in the Southern District of Texas, the FTC alleges that USAP and Welsh Carson:

    • Executed a “roll-up” strategy, buying up over a dozen large anesthesia practices in Texas over about a decade to create a single dominant provider (with allegedly ~70 percent share by revenue and ~60 percent share of cases for hospital-only anesthesia services in several geographies) that commanded higher prices;
    • Drove up anesthesia prices further through price-setting agreements with independent providers that allowed USAP to bill payers for anesthesia services offered by both groups at USAP’s higher rates; and
    • Eliminated competition by securing a large rival anesthesiology provider’s agreement to stay out of USAP’s territory.

    According to the FTC, this anticompetitive conduct, along with high switching costs for hospitals and high barriers to entry, allowed USAP to retain nearly all of its hospital contracts even while charging the highest rates for anesthesia services. The complaint alleges this conduct violates Section 1 of the Sherman Act (prohibiting agreements in restraint of trade), Section 2 of the Sherman Act (prohibiting monopolization), Section 7 of the Clayton Act (prohibiting transactions that may substantially lessen competition or tend to create a monopoly) and Section 5(a) of the FTC Act (prohibiting unfair methods of competition).

    “Private equity firm Welsh Carson spearheaded a roll-up strategy and created USAP to buy out nearly every large anesthesiology practice in Texas. Along with a set of unlawful agreements to set prices and allocate markets, these tactics enabled USAP and Welsh Carson to raise prices for anesthesia services — raking in tens of millions of extra dollars for these executives at the expense of Texas patients and businesses,” said FTC Chair Lina Khan.

    The FTC’s suit against USAP and Welsh Carson is only the latest salvo in the government’s campaign to increase scrutiny of private equity deals. While this case appears to have some extreme facts, with a roll-up strategy being used to create a dominant anesthesia provider and the protection of that dominance through price-setting and market allocation agreements, it highlights the need for private equity firms to carefully consider antitrust issues at the outset of a roll-up strategy.

    It is important to note that the FTC lawsuit does not mean that all private equity firms engaging in serial acquisitions should expect an investigation, as the allegations here involve both market concentration and market conduct. As Rahul Rao, deputy director of the FTC’s Bureau of Competition, noted in his remarks during the American Bar Association antitrust law section’s most recent annual spring meeting, private equity is “not a monolith” and not all firms use the tactics that concern the agencies. Catherine Reilly, the DOJ Antitrust Division’s counsel for civil operations, also acknowledged that private equity firms are not all alike and that some could even be considered as divestiture buyers.

    Why is this important?

    The FTC’s lawsuit against USAP and Welsh Carson is notable in a few respects.

    First litigated challenge to serial acquisitions. While both the FTC and the Department of Justice (“DOJ”) have expressed concern over the potential cumulative impact of serial or roll-up acquisitions, the suit is the FTC’s first litigated challenge directed at this strategy. Individually, these smaller acquisitions often fall below the notification thresholds of the Hart-Scott-Rodino (“HSR”) Act, which can allow an acquiring firm to grow market share without antitrust scrutiny — at least until now. The FTC asserts in its complaint that roll-up acquisitions violate the antitrust laws whether considered individually or in the aggregate. In an opinion piece for the Financial Times, Chair Khan argues that federal antitrust laws “can be squarely applied to a wide range of business practices, including serial acquisitions” and states in the FTC’s accompanying press release that the agency “will continue to scrutinize and challenge serial acquisitions, roll-ups, and other stealth consolidation schemes that unlawfully undermine fair competition and harm the American public.”

    Targeting of minority private equity investor. Alongside USAP, the FTC is suing one of the company’s private equity backers. Despite the fact that Welsh Carson is a minority stakeholder (alongside Berkshire Partners and GIC Capital), the FTC alleges that Welsh Carson effectively controls USAP and that it masterminded the “multi-year anticompetitive scheme.” Consistent with Chair Khan’s assertion in her Financial Times op-ed that the antitrust laws “may apply to parent companies and investors if they directly participate or conspire to participate in anti-competitive conduct,” the FTC claims that Welsh Carson “formulated, directed, controlled, had the authority to control, dictated, encouraged, or actively and directly participated” in USAP’s allegedly anticompetitive conduct. In particular, the complaint focuses on Welsh Carson general partner Brian Regan’s role in allegedly facilitating the USAP’s scheme by signing deal documents, leading negotiations for USAP’s alleged market allocation agreement with a rival provider, identifying acquisition targets, securing funding and negotiating with insurers.

    Pattern of heightened regulatory concern over private equity roll-ups continues. As we discussed in a previous Alert, private equity transactions, once considered unlikely to raise significant antitrust concerns, have been put in the crosshairs by the Biden administration. Agency leadership consistently has signaled in public statements its distrust of roll-ups and, in recent months, has moved beyond “talking the talk” to “walking the walk.” Their actions include proposing changes to the HSR notification form to gather information about private equity structures and proposing changes to the merger guidelines enabling the review of serial acquisitions and partial ownership, as well as imposing broad prior approval and prior notice requirements in a consent decree for another private equity deal.

    Agency rhetoric targeting private equity roll-ups. Both the FTC and the DOJ have been vocal about the need to examine private equity transactions, particularly in the healthcare space and particularly with regard to serial acquisitions. Assistant Attorney General Jonathan Kanter argued in May 2022 that the roll-up model is “often very much at odds with the law and very much at odds with the competition we’re trying to protect,” and has warned that a fuller assessment of these deals is “top of mind.” Deputy Assistant Attorney General Andrew Forman stated in a June 2022 speech that the DOJ is “focused on potential antitrust enforcement on private equity ‘roll-ups,’ namely whether in particular circumstances a series of often smaller transactions can cumulatively or otherwise lead to a substantial lessening of competition or tendency to create a monopoly.” Chair Khan echoed those comments, advocating for a more “muscular” approach to reviewing private equity deals and stating that “a huge private equity firm controlling, say, veterinary clinics” could be of concern even if the individual acquisitions might not raise issues.

    Prior approval and prior notice requirements. In June 2022, the FTC announced a consent agreement with JAB Consumer Partners (“JAB”) in connection with its acquisition of a series of veterinary clinics that included a prior approval requirement for future acquisitions in the relevant markets, as well as a broad and “first of its kind” requirement that JAB provide advance notice to the FTC before the acquisition of any US veterinary clinic within 25 miles of any clinic owned by JAB. The requirements were imposed to curtail JAB’s ability to continue with what Chair Khan termed “‘buy-and-buy’ tactics” that allow firms to “roll up sectors” and “accrue market power and reduce incentives to compete, potentially leading to increased prices and degraded quality.” Chair Khan stated that these types of prior approval and prior notice remedies will “allow the FTC to better address stealth roll-ups by private equity firms.”

    Proposed changes to HSR form and merger guidelines. The agencies also focused on private equity roll-ups in their proposed changes to both the premerger notification form required by the HSR Act and the draft merger guidelines, which we have written about previously. The expanded obligations proposed in June 2023 by the FTC to the HSR form would include requirements aimed at uncovering roll-up strategies through the disclosure of acquisitions in the preceding 10 years in any industry where the parties report a horizontal overlap, even if those transactions were not previously reported to the agencies due to their smaller size. The draft merger guidelines jointly released in July 2023 by the FTC and the DOJ include a guideline specifically allowing the agencies to consider the cumulative effect of an entire series of acquisitions, rather than just an individual deal, to determine if a firm may have violated antitrust laws.

    Takeaways

    • The FTC’s suit against USAP and Welsh Carson gave teeth to increasing rhetoric from both agencies against private equity consolidation in the healthcare space. The lawsuit also made good on the FTC’s stated intentions to enforce antitrust laws against serial acquisitions. Given the provisions specific to roll-ups in both the proposed changes to the HSR notification form and the proposed draft merger guidelines, as well as statements made by DOJ and FTC leadership, we can expect similar lawsuits or enforcement actions challenging the cumulative effect of roll-up or serial acquisitions to follow.
    • The legitimacy of the agencies’ position will be determined in court. Although the agencies’ recent litigation track record may not bode well for the FTC, regardless of the ultimate outcome of the suit against USAP and Welsh Carson, firms that have pursued or are considering roll-up strategies, particularly in healthcare, should evaluate their market positions and assess the risk that they might be targeted by a similar action. The risk of investigation increases if market consolidation is accompanied by price hikes or other conduct that may reduce or eliminate competition (e.g., price fixing or setting, market allocation agreements, etc.).
    • Even though the FTC does not allege anticompetitive acts by USAP or Welsh Carson in markets outside of Texas (or other markets in Texas outside of anesthesiology), the FTC seeks to enjoin Welsh Carson “from engaging in similar and related conduct in the future,” in addition to the equitable relief it seeks from USAP (including divestitures). The complaint alleges that Welsh Carson has pursued and will continue to pursue similar rollup strategies in anesthesiology and other medical specialties, such as emergency medicine and radiology, in violation of the antitrust laws. If the FTC is successful, the court could issue an injunction similar to the JAB consent decree requiring Welsh Carson to seek prior approval from the FTC before making acquisitions of anesthesiology practices in Texas and also to give prior notice to the FTC of acquisitions of anesthesiology practices in other states or perhaps acquisitions of any medical specialties in the US. This broad relief would potentially interfere with Welsh Carson’s ability to make future acquisitions in other markets.

    Authored by Peter Jonathan Halasz and Ngoc Pham Hulbig.

    If you have any questions concerning this Alert, please contact your attorney at Schulte Roth & Zabel or one of the authors.


    This communication is issued by Schulte Roth & Zabel LLP for informational purposes only and does not constitute legal advice or establish an attorney-client relationship. In some jurisdictions, this publication may be considered attorney advertising. © 2023 Schulte Roth & Zabel LLP. All rights reserved. SCHULTE ROTH & ZABEL is the registered trademark of Schulte Roth & Zabel LLP.

    In depth
    Authors

    Peter Jonathan Halasz

    Of Counsel

    New York – 919 Third Avenue

    More insights

  • Healthcare Regulatory Check-up Newsletter | August 2023 Recap

    Healthcare Regulatory Check-up Newsletter | August 2023 Recap

    ARTICLE / REPORT

    Healthcare Regulatory Check-up Newsletter | August 2023 Recap

    September 26, 2023

    Read time: 2 min

    Overview

    This issue of McDermott’s Healthcare Regulatory Check-Up highlights significant regulatory activity for August 2023. We discuss several criminal and civil enforcement actions that involve violations of the False Claims Act (FCA) and the Anti-Kickback Statute (AKS). We also review major reimbursement regulatory updates and a recent advisory opinion issued by the Office of the Inspector General (OIG) raising concerns about a perceived “contractual joint venture.”

    In depth
    Tabs

    Tony Maida

    Partner

    New York – One Vanderbilt Avenue

    James A. Cannatti III

    Partner

    Washington, DC

    Emily Jane Cook

    Partner

    Los Angeles, Washington, DC

    Monica Wallace

    Partner

    Chicago

    Callee Donovan

    Associate

    Boston

    More insights
    Endnotes